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(50.1%), mucocutaneous (47.4%), and gastrointestinal symp-
toms (31.3%). A total of 249 different drugs were involved. 
DIAs were mainly caused by antibiotics (39.3%), traditional 
Chinese medicines (TCM) (11.9%), radiocontrast agents 
(11.9%), and antineoplastic agents (10.3%). Cephalospor-
ins accounted for majority (34.5%) of antibiotic-induced 
anaphylaxis, followed by fluoroquinolones (29.6%), beta-
lactam/beta-lactamase inhibitors (15.4%) and penicillins 
(7.9%). Blood products and biological agents (3.1%), and 
plasma substitutes (2.1%) were also important contributors 
to DIAs. Conclusion A variety of drug classes were impli-
cated in DIAs. Patients should be closely monitored for signs 
and symptoms of anaphylaxis when medications are admin-
istered especially with antibiotics, TCM, radiocontrast and 
antineoplastic agents.
Keywords China · Clinical features · Drug category · 
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Abstract Background Few studies on the causes of 
drug-induced anaphylaxis (DIA) in the hospital setting are 
available. Objective We aimed to use the Beijing Pharma-
covigilance Database (BPD) to identify the causes of DIA 
in Beijing, China. Setting Anaphylactic case reports from 
the BPD provided by the Beijing Center for Adverse Drug 
Reaction Monitoring. Method DIA cases collected by the 
BPD from January 2004 to December 2014 were adjudi-
cated. Cases were analyzed for demographics, causative 
drugs and route of administration, and clinical signs and 
outcomes. Main outcome measure Drugs implicated in DIAs 
were identified and the signs and symptoms of the DIA cases 
were analyzed. Results A total of 1189 DIA cases were ana-
lyzed. The mean age was 47.6 years, and 732 (61.6%) were 
aged from 18 to 59 years. A total of 627 patients (52.7%) 
were females. There was a predominance of cardiovascular 
(83.8%) followed by respiratory (55.4%), central nervous 
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Impacts on practice
• Drug-induced anaphylaxis accounts for at least 12% of 
adverse drug event reports in Chinese hospitals collected 
by the Beijing Pharmacovigilance Database between 
2004 to 2014, and the associated mortality rate is 3.3%.
• The top four drug categories implicated in drug 
induced anaphylaxis cases in China are antibiotics, 
traditional Chinese medicines, radiocontrast media 
and antineoplastic agents.
• Drug induced anaphylaxis most often presents 
with cardiovascular system symptoms, followed by 
mucocutaneous, respiratory and central nervous sys-
tem symptoms.
Introduction
Anaphylaxis is a severe, life-threatening, systemic allergic 
reaction that occurs rapidly after contact with an inducing 
substance. Common triggers of anaphylaxis include food, 
insect stings, drugs and latex [1, 2]. Susceptibility (or 
incidence) of anaphylaxis varies with age, allergen expo-
sure, and predisposing genetic factors [1, 3]. Symptoms 
of anaphylaxis may progress rapidly and involve multiple 
target organ systems including the integumentary, respira-
tory, gastrointestinal, and cardiovascular systems [1].
Of the most common triggers of anaphylaxis [1, 2], 
drugs are considered to be the primary triggers in adults 
[1, 4]. Administration of any drug by any route can poten-
tially cause anaphylaxis [2, 5]. According to a retrospec-
tive U.S. epidemiology study, medications were the most 
common cause (58.8%) of 2458 anaphylaxis-related 
deaths from 1999 to 2010 [6]. Furthermore, a multicenter 
retrospective study from Korea, drug-induced anaphy-
laxis (DIA) accounted for 46.5% of all 1806 anaphylaxis 
cases, becoming the most common trigger of anaphylaxis 
in Korea [7].
Although the epidemiological data of DIA have been 
reported in western countries [6, 8, 9], data is limited in 
Asian population. Most published studies are case reports 
or case series focused on specific drugs such as antibiot-
ics or special clinical situations for instance during perio-
perative procedures. Studies are needed to confirm the 
previous findings and to add new knowledge to this area 
in Asian population. Our previous study assessed the use 
of epinephrine in managing patients with DIA through 
the analysis of the Beijing Pharmacovigilance Database 
(BPD) [10], and the present study is an extension of this 
project to provide a detailed analysis of the reported DIA 
cases.
Aim of the study
The objective of this study was to contribute to a better 
understanding of DIAs in Beijing, China, based on anaphy-
laxis case reports by the BPD over a decade period. The 
following information was extracted and analyzed: causative 
drugs, clinical features and severities of DIA cases.
Ethics approval
This study was considered to be exempt from further review 
by the Institutional Review Board, Peking University Third 
Hospital. Patient informed consent was not required because 
this was a retrospective study using only de-identified data.
Method
Using a structured database inquiry, extraction, and case 
adjudication methodology as reported in our previous study 
[10], we performed a detailed analysis on DIA cases. The 
cases were reported to the BPD from January 1, 2004 to 
December 31, 2014.
In contrast with our previous study [10], anaphylaxis-
inducing drugs were classified into various pharmacothera-
peutic groups according to the Martindale—The Complete 
Drug Reference (37th edition) [11], World Health Organi-
zation (WHO) Model Formulary (2008) [12], and Chinese 
Pharmacopoeia (ChP) [13]. Within each group there were 
several subgroups. Previously, cases in which more than one 
drug was suspected were defined as “Associations” [10]. In 
this study, we further classified drugs under the “Associa-
tions” according to the original judgments of physicians 
when information is available. For example, a case was 
reported in which two drugs were administered to a patient-
Ambroxol injection and Lomefloxacin injection. Clinicians 
filing the report deemed that Lomefloxacin injection was 
more likely to induce anaphylaxis. Accordingly, we classi-
fied this case into “Antibiotics” instead of “Associations”. 
For each DIA case, we assessed the case severity into three 
grades: grade 1 category was patients with only cutaneous 
involvement, grade 2 included patients with mild-to-mod-
erate manifestations of anaphylaxis, and those with grade 
3 reactions had severe presentations with cutaneous, gas-
trointestinal, and potentially life-threatening respiratory or 
cardiovascular signs and symptoms [14].
Statistical analysis
The statistical analysis was performed using the SPSS 
version 22 (SPSS Inc., IL, USA). Continuous variables 
were subjected to normality tests using the single sample 
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Kolmogorov–Smirnov test, where data in accordance with 
normal distribution was expressed as mean ± standard 
deviation, while those in accordance with the non-normal 
distribution was expressed as median (min, max), and 
the dichotomous variables were described as frequency 
(percentage).
Results
Demographic and clinical characteristics
A total of 9425 patients with drug-induced hypersensitivity 
reactions were identified from the BPD. After initial screen-
ing and adjudication, 1189 patients were ultimately included 
in our analysis [10]. Of these patients, the mean age was 
47.6 years, 732 (61.6%) were aged from 18 to 59 years. A 
total of 627 (52.7%) were female patients (Table 1).
The majority of patients (83.8%) experienced cardiovas-
cular anaphylactic symptoms; the percentage of patients who 
developed mucocutaneous compromise, respiratory com-
promise, central nervous symptoms were 47.4, 55.4, and 
50.1%, respectively. Gastrointestinal anaphylactic symptoms 
occurred in 31.3% of the cases. Overall, 73 (6.1%) of the 
patients were admitted to intensive care units (ICU), and 39 
(3.3%) patients died during their hospitalizations as a result 
of anaphylaxis.
Drug triggers
A total of 249 individual drugs were involved in the ana-
phylactic cases analyzed, classified into 23 pharmacothera-
peutic groups and 53 subgroups. A total of 1145 (96.3%) 
cases were attributed to single drugs, and 44 (3.7%) were 
attributed to “Associations” (Table 2). While various drug 
triggers were reported, the main four general categories for 
DIAs were antibiotics (39.3%), traditional Chinese medi-
cines (TCM, 11.9%), radiocontrast agents (11.9%) and anti-
neoplastic agents (10.3%).
Antibiotics held the leading trigger medications of drug-
induced anaphylaxis (467/1189, 39.3%). Among the anti-
biotics, the top three sub-groups included beta-lactams 
(275/467, 58.9%), fluoroquinolones (138/467, 29.6%), and 
macrolides (28/467, 6.0%) (Table 3). Within the beta lac-
tams in particular, cephalosporins (161/275, 58.5%) were 
identified the most followed by beta-lactam/beta-lactamase 
inhibitors (72/275, 26.2%) and penicillins (37/275, 13.5%) 
(Table 3).
There were 141 DIA cases (11.9%) induced by TCMs, 
most cases involving TCM injections (135/141, 95.7%), with 
the remaining cases including oral or topical TCM formula-
tions. A total of 36 different TCM injections were identified. 
These injections were mainly used for the treatment of car-
diovascular and cerebrovascular disease, digestive system dis-
ease, respiratory system disease, and cancer. Ciwujia was the 
leading cause followed by Qingkailing, Houttuynia cordata, 
Shuxuening, Shuanghuanglian, Chuanhuning, Safflower and 
Yinxingdamo (Tables 2, 4). Other TCM injections (53 cases) 
were listed in Appendix 1 in the electronic supplementary 
materials.
Radiocontrast agents were reported 141 times, and the top 
three were contrast media used in X-ray (113/141, 80.1%), 
magnetic resonance imaging (12/141, 8.5%) and ophthalmic 
procedures (10/141, 7.1%) (Tables 2, 4).
Among the DIA cases caused by antineoplastic drugs 
(122/1189, 10.3%), paclitaxel (68/122, 55.7%) and platinum-
based antineoplastics (40/122, 32.8%) were important con-
tributors (Tables 2, 4). The remaining identified DIA cases 
(274) were listed in Table 2.
There were 149 anaphylaxis cases occurred during perio-
perative procedures, and the top three drug groups involved 
were antibiotics (43.0%), radiocontrast agents (14.8%) and 
plasma substitutes (9.4%) (Appendix 2).
Most causative drugs were administered by the intrave-
nous route (86.4%), oral route (5.4%), intramuscular route 
(3.0%), subcutaneous route (1.6%), and intra-arterial route 
(1.4%). There were 12 cases of anaphylactic reactions 
occurred during intradermal tests.
Table 1  Demographics, clinical characteristics and outcome of 
patients with drug-induced anaphylaxis
ED emergency department, ICU intensive care unit
Variable Value, no. (%) 95% CI
Demographics
 Age
  Mean—year 47.6 ± 20.1
  < 18 year 91 (7.7) 6.2–9.3
  18–59 year 732 (61.6) 58.8–64.4
  ≥60 year 366 (30.8) 28.2–33.5
 Female 627(52.7) 50.0–55.5
 Male 562(47.3) 44.5–50.0
Organ system involvement
 Cardiovascular 996 (83.8) 81.3–85.8
 Respiratory 659 (55.4) 52.5–58.3
 Central nervous system 596 (50.1) 47.4–53.1
 Mucocutaneous 563 (47.4) 44.6–50.5
 Gastrointestinal tract 372 (31.3) 28.8–33.9
Severity of anaphylaxis
 Mild to moderate 160 (13.5) 11.5–15.6
 Severe 1029 (86.5) 84.4–88.5
Outcome
 ICU admission 73 (6.1) 4.9–7.8
 Death 39 (3.3) 2.3–4.3
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Table 2  Pharmacotherapeutic 
groups and subgroups involved 
of drug-induced anaphylaxis
Drugs Value, no. (%) 95% CI
Total 1189
Antibiotics 467 (39.3) 36.7–42.1
 β-lactams 275 (23.1) 21.0–25.5
 Fluoroquinolones 138 (11.6) 9.8–13.4
 Macrolides 28 (2.4) 1.6–3.3
 Other  antibioticsa 26 (2.2) 1.3–3.0
TCM 141 (11.9) 10.2–14.3
 TCM (injection) 135 (11.4) 9.5–13.2
 TCM (oral) 5 (0.4) 0.1–0.8
 TCM (topical) 1 (0.1) 0.0–0.3
Radiocontrast agents 141 (11.9) 10.2–14.3
 X-ray contrast media, iodinated 113 (9.5) 7.8–11.3
 MRI contrast media 12 (1.0) 0.5–1.6
 Ophthalmic medicines 10 (0.8) 0.3–1.4
 Ultrasound contrast agents 4 (0.3) 0.1–0.8
 Otherb 2 (0.2) 0.0–0.4
Antineoplastics 122 (10.3) 8.8–12.4
 Taxanes 73 (6.1) 4.9–7.6
 Platinum compounds 40 (3.4) 2.4–4.5
 Cytotoxic antibiotics 5 (0.4) 0.1–0.8
 Alkylating agents 2 (0.2) 0.0–0.4
 Teniposide 1 (0.1) 0.0–0.3
 Asparaginase 1 (0.1) 0.0–0.3
Blood products, Biologics and plasma substitutes 74 (6.2) 4.9–7.7
 Blood products and Biologics 37 (3.1) 2.2–4.2
 Plasma substitutes 25 (2.1) 1.3–3.0
 Monoclonal antibodies 12 (1.0) 0.5–1.6
Anesthetics 25 (2.1) 1.3–3.0
 Local anesthetics 10 (0.8) 0.3–1.4
 NMBAs 12 (1.0) 0.5–1.6
 General anesthetics 3 (0.3) 0.0–0.6
 Vaccines, immunoglobulins and antiserums 23 (1.9) 1.2–2.8
 Immunoglobulins and antiserums 19 (1.6) 0.9–2.4
 Vaccines 4 (0.3) 0.1–0.7
Nutrition and vitamins 22 (1.9) 1.1–2.7
 Vitamins and minerals 16 (1.3) 0.8–2.1
 Amino acids and fat emulsions 6 (0.5) 0.2–0.9
Immune-modulators 21 (1.8) 1.0–2.5
 Immunostimulants 16 (1.3) 0.8–1.9
 Immunosuppressants 5 (0.4) 0.1–0.8
Blood system medications 20 (1.7) 0.9–2.4
 Antifibrinolytic agents and hemostatics 11 (0.9) 0.4–1.5
 Iron (injection) 6 (0.5) 0.2–1.0
 Anticoagulants 2 (0.2) 0.0–0.4
 Antiplatelet agents 1 (0.1) 0.0–0.3
Analgesics, anti-inflammatory drugs and antipyretics 17 (1.4) 0.8–2.2
 NSAIDs 11 (0.9) 0.4–1.6
 Opioids 5 (0.4) 0.1–0.8
 Paracetamol 1 (0.1) 0.0–0.3
Hormones, other endocrine medicines 16 (1.3) 0.8–2.1
 Corticosteroids 11 (0.9) 0.4–1.5
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Of the 44 DIA cases caused by the association of two or 
more drugs, 14 (31.8%) anaphylaxis cases involved one or 
more TCM combined with one or more other non-TCM, 12 
(27.3%) occurred during general anesthesia, and 21 (47.7%) 
included antibiotics (Appendix 3).
Severity and anaphylaxis‑related deaths
Among the 1189 DIA cases, 1029 (86.5%) were considered 
as severe (grade 3) and 39 (3.3%) were fatal. Mortality was 
due mainly to the following top four medication groups: 
antibiotics (13/39, 33.3%), radiocontrast agents (12/39, 
30.8%), antineoplastic agents (4/39, 10.3%), TCM injections 
(3/39, 7.7%). The detailed information was listed in Table 5.
Discussion
To our knowledge, this is the first analysis of drug-induced 
anaphylaxis in the hospital setting in China. Using the Bei-
jing Pharmacovigilance Database, our study shows that there 
were 1189 DIA cases in clinical settings over a decade in 
Beijing, China, accounting for 12.6% of all ADE reports col-
lected by the BPD. The percentage of DIA in Beijing, China 
is higher than the percentage of DIA in Portugal (5–7%) 
spanning over a decade [8]. Patients aged between 18 and 
59 years (61.6%) had the highest frequency of DIA among 
all three age groups, which is consistent with a recent study 
in China by Jiang et al. [15]. Similar to most studies [8, 9, 
16], females had a higher frequency of anaphylaxis com-
pared to males in our analysis. A high proportion of patients 
TCM traditional Chinese medicine, NSAIDs non-steroidal anti-inflammatory drugs, MRI magnetic reso-
nance imaging, NMBAs neuromuscular blocking agents, ACEI angiotensin converting enzyme inhibitor; BB 
beta-blocker, PPI proton pump inhibitor
a Other antibiotics included aminoglycosides, clindamycin, vancomycin, and metronidazole
b Other radiocontrast agent was indocyanine green injection
c Associations were defined as those cases in which more than one medication was suspected to cause the 
anaphylaxis. Details of anaphylaxis induced by associations were listed in Appendix 3
d “Others” category included monosialotetrahexosylganglioside sodium for injection, sodium deoxyribonu-
cleotide injection, cerebroprotein hydrolysate for injection, and coenzyme A for injection
Table 2  (continued) Drugs Value, no. (%) 95% CI
 Hypothalamic and pituitary hormones 4 (0.3) 0.1–0.7
 Insulins 1 (0.1) 0.0–0.3
Prostaglandins 10 (0.8) 0.3–1.4
Cardiovascular medications 11 (0.9) 0.4–1.5
 Vasodilators 5 (0.4) 0.1–0.8
 Antiarrhythmics 3 (0.3) 0.0–0.6
 ACEI/BB 2 (0.2) 0.0–0.4
 Statins 1 (0.1) 0.0–0.3
Gastrointestinal medicines 8 (0.7) 0.3–1.1
 H2 receptor blockers 3 (0.3) 0.0–0.6
 Laxatives 2 (0.2) 0.0–0.4
 PPI 1 (0.1) 0.0–0.3
 Antacids 1 (0.1) 0.0–0.3
 Antiemetics 1 (0.1) 0.0–0.3
Antidotes 7 (0.6) 0.3–1.1
Antivirals 5 (0.4) 0.1–0.8
Antifungals 3 (0.3) 0.0–0.6
Psychotherapeutic medicines 3 (0.3) 0.0–0.6
 Antidementia medicines 2 (0.2) 0.0–0.4
 Antipsychotic medications 1 (0.1) 0.0–0.3
Respiratory medications 3 (0.3) 0.0–0.6
 Expectorants 2 (0.2) 0.0–0.4
 Bronchodilators 1 (0.1) 0.0–0.3
Calcium regulating drugs 1 (0.1) 0.0–0.3
Associationsc 44 (3.7) 2.7–4.9
Othersd 5 (0.4) 0.1–0.8
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developed cardiovascular symptoms (83.8%), and the mor-
tality rate of 3.3% is comparable to previous studies [17, 18].
Antibiotic‑induced anaphylaxis
Of all DIAs reported in BPD and included within our analy-
sis, antibiotics attributed to the most common cause of DIA 
(39.3%), comparable to the incidence of antibiotic-induced 
anaphylaxis within the U.S. (40.5%) [6]. However, antibi-
otic-induced anaphylaxis occurred more frequently than 
reports from Korea (10.5%) [7] and Portugal (16.7%) [8]. In 
agreement with previous reports, anaphylaxis from β-lactam 
antibiotics (58.9%) were reported more frequently than non-
β-lactam antibiotics [19]. Cephalosporins accounted for the 
majority of β-lactam antibiotic-related anaphylaxis followed 
by beta-lactam/beta-lactamase inhibitors and penicillins. 
This may be explained partly by the greater use of cepha-
losporins in Chinese hospitals [20]. The likelihood of ana-
phylaxis from penicillins can be assessed by skin tests [19]. 
However, routine intradermal skin testing of a cephalosporin 
may not be useful for predicting an immediate hypersensi-
tivity because of the extremely low test sensitivity, which 
was confirmed by a recent retrospective study conducted by 
Yoon et al. [21]. Fluoroquinolone antibiotics also accounted 
for a high proportion of all 1189 anaphylaxis cases (11.6%), 
which is consistent with the frequency (11.7%) found by 
Faria et al. [16]. The high frequency of anaphylaxis from 
fluoroquinolones maybe due to the overuse of fluoroqui-
nolone antibiotics in China [20], and the hypersensitivity to 
quinolones is less likely to be determined from skin testing 
[2].
Given that antibiotics are the most common trigger 
for anaphylaxis, the importance of inquiring and docu-
menting patient’s medication allergic history cannot be 
Table 3  Drugs of antibiotic-induced anaphylaxis
Antibiotics ATC-codes All Patients 
(n = 467) Value, 
no. (%)
β-Lactam antibiotics 275 (58.9)
 Cephalosporins 161 (34.5)
  First-generation J01DB 13 (2.8)
   cefradine J01DB09 4 (0.9)
   cefalexin J01DB01 4 (0.9)
   cefazolin J01DB04 3 (0.6)
   cefadroxil J01DB05 1 (0.2)
   cefathiamidine NA 1 (0.2)
  Second-generation J01DC 86 (18.4)
   cefuroxime J01DC02 54 (11.6)
   cefmetazole J01DC09 18 (3.9)
   cefoxitin J01DC01 6 (1.3)
   cefotiam J01DC07 3 (0.6)
   cefminox J01DC12 2 (0.4)
   cefamandole J01DC03 2 (0.4)
   cefaclor J01DC04 1 (0.2)
  Third-generation J01DD 58 (12.4)
   ceftriaxone J01DD04 35 (7.5)
   ceftazidime J01DD02 10 (2.1)
   ceftizoxime J01DD07 6 (1.3)
   cefoperazone J01DD12 4 (0.9)
   cefotaxime J01DD01 2 (0.4)
   cefdinir J01DD15 1 (0.2)
  Fourth-generation J01DE 4 (0.9)
   cefepime J01DE01 4 (0.9)
β-lactam + β-lactamase inhibitors 72 (15.4)
  cefoperazone + sulbactam J01DD62 45 (9.6)
  piperacillin + sulbactam J01CR05 12 (2.6)
  piperacillin + tazobactam J01CR05 5 (1.1)
  ampicillin + sulbactam J01CA51 5 (1.1)
  amoxicillin + clavulanic acid J01CR02 3 (0.6)
  imipenem + cilastatin J01DH51 1 (0.2)
  amoxicillin + sulbactam J01CR02 1 (0.2)
Penicillins J01C 37 (7.9)
 benzylpenicillin J01CE01 23 (4.9)
 Penicillins with extended spec-
trum (aminopenicillins)
J01CA 14 (3.0)
   azlocillin J01CA09 5 (1.1)
   amoxicillin J01CA04 5 (1.1)
   mezlocillin J01CA10 4 (0.9)
Others 5 (1.1)
  aztreonam J01DF01 3 (0.6)
  latamoxef J01DD06 2 (0.4)
Fluoroquinolones J01MA 138 (29.6)
 levofloxacin J01MA12 82 (17.6)
 moxifloxacin J01MA14 23 (4.9)
 gatifloxacin J01MA16 14 (3.0)
 pefloxacin J01MA03 5 (1.1)
ATC anatomical therapeutic chemical, NA not available
Table 3  (continued)
Antibiotics ATC-codes All Patients 
(n = 467) Value, 
no. (%)
 ofloxacin J01MA01 4 (0.9)
 fleroxacin J01MA08 4 (0.9)
 ciprofloxacin J01MA02 4 (0.9)
 lomefloxacin J01MA07 2 (0.4)
Macrolides J01FA 28 (6.0)
 azithromycin J01FA10 28 (6.0)
clindamycin J01FF01 14 (3.0)
Aminoglycosides J01G 8 (1.7)
 etimicin NA 7 (1.5)
 gentamicin J01GB03 1 (0.2)
vancomycin J01XA01 3 (0.6)
metronidazole J01XD01 1 (0.2)
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underestimated. This is the area pharmacists could contrib-
ute to patient safety. Clinical symptoms and signs related to 
anaphylaxis should be closely monitored when antibiotics, 
especially cephalosporins and fluoroquinolones, are admin-
istered to patients in the hospital setting.
TCM‑induced anaphylaxis
The use of TCM was the second most common drug trigger 
in our analysis, and almost all (95.7%) TCM-related ana-
phylactic cases were from injectable TCM formulations. 
Table 4  Drugs of 
radiocontrast-induced 
anaphylaxis, TCM injection-
induced anaphylaxis, and 
antineoplastics-induced 
anaphylaxis
TCM traditional Chinese medicine, ATC anatomical therapeutic chemical, NA not available
a Only the top 8 common TCMs were listed; detailed information on the Others category was presented in 
Appendix 1 in the electronic supplementary materials
Drugs ATC-codes Value, no. (%)
Radiocontrast agents (n = 141)
 iopromide  V08AB05 52 (36.9)
 iohexol V08AB02 26 (18.4)
 iopamidol V08AB04 16 (11.3)
 fluorescein sodium NA 10 (7.1)
 gadopentetic acid (gadopentetate dimeglumine) V08CA01 9 (6.4)
 ioversol V08AB07 7 (5.0)
 iobitridol V08AB11 5 (3.5)
 iodixanol V08AB09 5 (3.5)
 sulfur hexafluoride V08DA05 4 (2.8)
 diatrizoic acid (meglumine diatrizoate) V08AA01 2 (1.4)
 indocyanine green NA 2 (1.4)
 gadobenic acid (gadobenate dimeglumine) V08CA08 1 (0.7)
 gadodiamide V08CA03 1 (0.7)
 gadoteric acid (gadoterate meglumine) V08CA02 1 (0.7)
TCM injections (n = 135)
 Ciwujia NA 21 (15.6)
 Qingkailing NA 16 (11.9)
 Houttuynia cordata NA 12 (8.9)
 Shuxuening NA 11 (8.1)
 Shuanghuanglian NA 6 (4.4)
 Chuanhuning NA 6 (4.4)
 Safflower NA 5 (3.7)
 Yinxingdamo NA 5 (3.7)
 Othersa NA 53 (39.3)
Antineoplastics (n = 122)
 paclitaxel L01CD01 68 (55.7)
 oxaliplatin L01XA03 18 (14.8)
 carboplatin L01XA02 13 (10.7)
 cisplatin L01XA01 7 (5.7)
 docetaxel L01CD02 5 (4.1)
 cyclophosphamide L01AA01 2 (1.6)
 doxorubicin  L01DB01 2 (1.6)
 nedaplatin NA 2 (1.6)
 topotecan  L01XX17 1 (0.8)
 epirubicin L01DB03 1 (0.8)
 bleomycin A5 NA 1 (0.8)
 mitomycin L01DC03 1 (0.8)
 asparaginase L01XX02 1 (0.8)
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The result is similar to a study reported by Jiang et al. [15]. 
TCM is unique to the Chinese population and therefore the 
DIAs associated with TCM is unique to that population as 
a result. Along with extensive indications for TCM, there is 
greater use of TCM injections compared to other countries. 
In our review, 36 different TCM injections were identified 
resulting in 11.4% of the anaphylaxis cases, among which 
three cases were fatal. The four most common triggers were 
injections of Ciwujia, Qingkailing, Houttuynia cordata and 
Shuxuening. The results were similar to those of Jiang et al., 
who found the most common triggers were injections of 
Qingkailing, Shuanghuanglian and Houttuynia cordata [15].
TCM injection is extracted from Chinese herbs, which 
may contain one or several active ingredients. The high fre-
quency of anaphylactic cases related to TCM injections may 
be explained as follows: (1) the components of a TCM injec-
tion are relatively complex and most formulations have not 
been thoroughly analyzed and identified; (2) a TCM injec-
tion also contains various additives, such as pigment, tan-
nin, starch and protein, and these additives may trigger the 
body’s immune system and cause anaphylaxis [22]; (3) qual-
ity control of TCM injections is relatively difficult due to the 
formulation complexity, and impurities may cause anaphy-
laxis as well; and (4) drug interactions between TCM injec-
tions and other medications should also be considered. Of 
the 135 patients who suffered anaphylaxis induced by TCM 
injections, patients’ age ranged from 4 to 90 years: chil-
dren under 18 years (5%), adults between 18 and 59 years 
(58.6%), and adults over 60 years (36.4%). This is consistent 
with a previous study reporting that patient of any age can 
suffer anaphylaxis induced by TCM injections [22]. There-
fore, caution should be exercised before considering the use 
of TCM and all patients regardless of age should be closely 
monitored during TCM administration.
Radiocontrast‑induced anaphylaxis
Our study found that radiocontrast agents were the third 
most common cause (11.9%) of DIA, coinciding with the 
frequency of previous studies in Korea (12.0%) [7]. How-
ever DIA through radiocontrast agents was reported less 
frequently than that in the United States (30.4%) [6]. Of 
these radiocontrast-induced anaphylaxis cases, the major-
ity (80.1%) were caused by iodine-based contrast agents. 
The number of anaphylaxis cases induced by iopromide 
(36.9%) were greater than any other non-ionic  iodi-
nated contrast agents, which is similar to the results from 
a previous study [23]. A recent retrospective study from 
Korea indicated that among the anaphylactic patients, 
iopromide was associated with more severe anaphylaxis 
with hypotension [24].
Patients with allergies, asthma, renal insufficiency, anxi-
ety, significant cardiac disease and other miscellaneous risk 
factors may be at an increased risk for anaphylactoid contrast 
reactions [25]. Patient’s medical history should be collected 
and the risk of contrast media induced anaphylactic reac-
tions should be assessment before contrast media administra-
tion. More importantly, appropriate resuscitative equipment 
should be available to treat anaphylactic reactions promptly. 
Table 5  Description of the anaphylaxis-related deaths
TCM traditional Chinese medicine, ATC anatomical therapeutic 
chemical, NA not available
a Associations were Moxifloxacin hydrochloride and sodium chloride 
injection, and Ambroxol hydrochloride for injection
Variable ATC-codes All patients 
(n = 39) value, 
no. (%)
Age
 Mean—year 53.8 ± 19.1
 < 18 year 1 (2.6)
 18–59 year 20 (51.3)
 ≥60 year 18 (46.1)
Female 14 (35.9)
Antibiotics 13 (33.3)
 cefuroxime J01DC02 5 (12.8)
 levofloxacin J01MA12 3 (7.7)
 ceftriaxone J01DD04 1 (2.6)
 ceftizoxime J01DD07 1 (2.6)
 cefepime J01DE01 1 (2.6)
 piperacillin + sulbactam J01CR05 1 (2.6)
 clindamycin J01FF01 1 (2.6)
Radiocontrast agents 12 (30.8)
 ioversol V08AB07 4 (10.3)
 iohexol V08AB02 3 (7.7)
 iopromide  V08AB05 2 (5.1)
 iopamidol V08AB04 1 (2.6)
 gadopentetic acid (gado-
pentetate dimeglumine)
V08CA01 1 (2.6)
 fluorescein sodium NA 1 (2.6)
Antineoplastics 4 (10.3)
 paclitaxel L01CD01 2 (5.1)
 oxaliplatin L01XA03 1 (2.6)
 asparaginase L01XX02 1 (2.6)
TCM injections 3 (7.7)
 Houttuynia cordata NA 2 (5.1)
 Chuanhuning NA 1 (2.6)
plasma substitutes 2 (5.1)
 hydroxyethyl starch B05AA07 1 (2.6)
 dextran B05AA05 1 (2.6)
Vaccine J07BB03 1 (2.6)
protamine V03AB14 1 (2.6)
articaine N01BB08 1 (2.6)
doxofylline R03DA11 1 (2.6)
Associationsa 1 (2.6)
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Premedications such as corticosteroids should also be used 
for pretreatment of “at-risk” patients who require a contrast-
enhanced examination [25].
Antineoplastics‑induced anaphylaxis
Antineoplastic agents were another frequent cause of 
DIA in the current study, consistent with those reported 
in literature [6, 8]. This may be related to the increasing 
chemotherapy use with ever increasing cancer prevalence 
in Beijing, China [26]. Paclitaxel accounted for 55.7% of 
antineoplastics-induced anaphylaxis, and the high fre-
quency may be related to the solubilizer, polyoxyethylene 
castor oil, which can induce anaphylaxis [27]. We also 
found that platinum-based agents accounted for 32.8% 
of all antineoplastics-induced anaphylaxis cases. Among 
these agents, oxaliplatin was a major trigger accounting for 
1.5% of all 1189 DIA cases, and this finding is consistent 
with a published study [28].
Although a recent study from Nonna et al. found that for 
patients with carboplatin induced hypersensitivity reaction, 
the use of oxaliplatin maybe a safer alternative [29], patients 
should be carefully monitored for signs and symptoms of 
anaphylaxis with any platinum-based chemotherapeutic 
agent.
Limitations
Our retrospective analysis was based on self-reported cases 
by health care professionals from the BPD, and therefore 
our study has the following limitations: (1) lack of the 
frequency of causative drug use as we could not obtain 
either prescription or reimbursement data; (2) we could 
not assess the prevalence of DIA in the region studied as 
we do not have the information of the total patient base; 
(3) potential reporting bias may exist: majority of reported 
cases were hospitalized patients in the non-ED setting, and 
only severe anaphylactic cases may have been reported; 
(4) we may not have included all DIA cases in the BPD: 
cases missed if clinicians did not report using the terms 
related to allergy or anaphylaxis or hypersensitivity (e.g. a 
patient with wheeze, vomiting, bronchospasm but was not 
described as “allergy” by clinicians when reporting to the 
BPD). In addition, some reported cases were not included 
due to insufficient information. Despite these limitations, 
the method we have taken should be robust against a range 
of potential biases: rigorous inclusion/exclusion criteria 
were utilized and all potential anaphylaxis cases were adju-
dicated by trained physician/allergists; and only patients 
with confirmed anaphylaxis and complete data record were 
included in the analysis.
Conclusion
This first detailed analysis of DIA case reports from 2004 to 
2014 in Chinese patients provides valuable information to 
clinicians. Antibiotics, TCM, radiocontrast media and anti-
neoplastic agents are the most common causes of DIA cases. 
The majority of DIA cases are considered to be severe with 
a high mortality rate of 3.3%. Pharmacists should be work-
ing closely with prescribers to assess each patient’s risks of 
developing anaphylaxis when drug therapy is involved, and 
to provide prompt treatment and resuscitations to reduce the 
morbidity and mortality when anaphylaxis occurs.
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